Noxopharm Quarterly Activities and Financial Update
Key points
- SOF-SKN to progress to an extension clinical study in CLE patients
- Promising data from immuno-oncology program
- CSL presents research involving Noxopharm technology at a global conference
Full summary
Noxopharm Limited, an Australian clinical-stage biotech company, has announced significant progress in its clinical and research activities. The company is preparing to commence an extension clinical study for its lead drug candidate, SOF-SKN, in patients with cutaneous lupus erythematosus (CLE) in Melbourne, Australia. This study aims to assess the safety and tolerability of SOF-SKN in CLE patients and generate initial signals of clinical efficacy. Noxopharm also reported promising data from its immuno-oncology program, which explores harnessing the immune system against cancer. Additionally, research involving Noxopharm's technology was presented at the International Society for Respiratory Viruses (ISRV) conference, demonstrating potential in reducing vaccine-related inflammation markers.
Guidance
Noxopharm had A$31k in cash as of 30 September 2026
Outlook
Noxopharm is exploring options to secure additional capital and is looking at its strategic plan for short-term catalysts.
Summary generated by a large language model. Please interpret with care.